Cargando…

Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials

Causality assessment for suspected drug-induced liver injury (DILI) during drug development and following approval is challenging. The IQ DILI Causality Working Group (CWG), in collaboration with academic and regulatory subject matter experts (SMEs), developed this manuscript with the following obje...

Descripción completa

Detalles Bibliográficos
Autores principales: Hey-Hadavi, Juliana, Seekins, Daniel, Palmer, Melissa, Coffey, Denise, Caminis, John, Abdullaev, Sandzhar, Patwardhan, Meenal, Tyler, Haifa, Raheja, Ritu, Stanley, Ann Marie, Pineda-Salgado, Liliam, Bourdet, David L., Andrade, Raul J., Hayashi, Paul H., Dimick-Santos, Lara, Rockey, Don C., Estilo, Alvin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184702/
https://www.ncbi.nlm.nih.gov/pubmed/33725335
http://dx.doi.org/10.1007/s40264-021-01051-5
_version_ 1783704632154914816
author Hey-Hadavi, Juliana
Seekins, Daniel
Palmer, Melissa
Coffey, Denise
Caminis, John
Abdullaev, Sandzhar
Patwardhan, Meenal
Tyler, Haifa
Raheja, Ritu
Stanley, Ann Marie
Pineda-Salgado, Liliam
Bourdet, David L.
Andrade, Raul J.
Hayashi, Paul H.
Dimick-Santos, Lara
Rockey, Don C.
Estilo, Alvin
author_facet Hey-Hadavi, Juliana
Seekins, Daniel
Palmer, Melissa
Coffey, Denise
Caminis, John
Abdullaev, Sandzhar
Patwardhan, Meenal
Tyler, Haifa
Raheja, Ritu
Stanley, Ann Marie
Pineda-Salgado, Liliam
Bourdet, David L.
Andrade, Raul J.
Hayashi, Paul H.
Dimick-Santos, Lara
Rockey, Don C.
Estilo, Alvin
author_sort Hey-Hadavi, Juliana
collection PubMed
description Causality assessment for suspected drug-induced liver injury (DILI) during drug development and following approval is challenging. The IQ DILI Causality Working Group (CWG), in collaboration with academic and regulatory subject matter experts (SMEs), developed this manuscript with the following objectives: (1) understand and describe current practices; (2) evaluate the utility of new tools/methods/practice guidelines; (3) propose a minimal data set needed to assess causality; (4) define best practices; and (5) promote a more structured and universal approach to DILI causality assessment for clinical development. To better understand current practices, the CWG performed a literature review, took a survey of member companies, and collaborated with SMEs. Areas of focus included best practices for causality assessment during clinical development, utility of adjudication committees, and proposals for potential new avenues to improve causality assessment. The survey and literature review provided renewed understanding of the complexity and challenges of DILI causality assessment as well as the use of non-standardized approaches. Potential areas identified for consistency and standardization included role and membership of adjudication committees, standardized minimum dataset, updated assessment tools, and best practices for liver biopsy and rechallenge in the setting of DILI. Adjudication committees comprised of SMEs (i.e., utilizing expert opinion) remain the standard for DILI causality assessment. A variety of working groups continue to make progress in pursuing new tools to assist with DILI causality assessment. The minimum dataset deemed adequate for causality assessment provides a path forward for standardization of data collection in the setting of DILI. Continued progress is necessary to optimize and advance innovative tools necessary for the scientific, pharmaceutical, and regulatory community. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40264-021-01051-5.
format Online
Article
Text
id pubmed-8184702
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-81847022021-06-25 Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials Hey-Hadavi, Juliana Seekins, Daniel Palmer, Melissa Coffey, Denise Caminis, John Abdullaev, Sandzhar Patwardhan, Meenal Tyler, Haifa Raheja, Ritu Stanley, Ann Marie Pineda-Salgado, Liliam Bourdet, David L. Andrade, Raul J. Hayashi, Paul H. Dimick-Santos, Lara Rockey, Don C. Estilo, Alvin Drug Saf Leading Article Causality assessment for suspected drug-induced liver injury (DILI) during drug development and following approval is challenging. The IQ DILI Causality Working Group (CWG), in collaboration with academic and regulatory subject matter experts (SMEs), developed this manuscript with the following objectives: (1) understand and describe current practices; (2) evaluate the utility of new tools/methods/practice guidelines; (3) propose a minimal data set needed to assess causality; (4) define best practices; and (5) promote a more structured and universal approach to DILI causality assessment for clinical development. To better understand current practices, the CWG performed a literature review, took a survey of member companies, and collaborated with SMEs. Areas of focus included best practices for causality assessment during clinical development, utility of adjudication committees, and proposals for potential new avenues to improve causality assessment. The survey and literature review provided renewed understanding of the complexity and challenges of DILI causality assessment as well as the use of non-standardized approaches. Potential areas identified for consistency and standardization included role and membership of adjudication committees, standardized minimum dataset, updated assessment tools, and best practices for liver biopsy and rechallenge in the setting of DILI. Adjudication committees comprised of SMEs (i.e., utilizing expert opinion) remain the standard for DILI causality assessment. A variety of working groups continue to make progress in pursuing new tools to assist with DILI causality assessment. The minimum dataset deemed adequate for causality assessment provides a path forward for standardization of data collection in the setting of DILI. Continued progress is necessary to optimize and advance innovative tools necessary for the scientific, pharmaceutical, and regulatory community. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40264-021-01051-5. Springer International Publishing 2021-03-16 2021 /pmc/articles/PMC8184702/ /pubmed/33725335 http://dx.doi.org/10.1007/s40264-021-01051-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Leading Article
Hey-Hadavi, Juliana
Seekins, Daniel
Palmer, Melissa
Coffey, Denise
Caminis, John
Abdullaev, Sandzhar
Patwardhan, Meenal
Tyler, Haifa
Raheja, Ritu
Stanley, Ann Marie
Pineda-Salgado, Liliam
Bourdet, David L.
Andrade, Raul J.
Hayashi, Paul H.
Dimick-Santos, Lara
Rockey, Don C.
Estilo, Alvin
Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
title Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
title_full Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
title_fullStr Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
title_full_unstemmed Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
title_short Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
title_sort overview of causality assessment for drug-induced liver injury (dili) in clinical trials
topic Leading Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184702/
https://www.ncbi.nlm.nih.gov/pubmed/33725335
http://dx.doi.org/10.1007/s40264-021-01051-5
work_keys_str_mv AT heyhadavijuliana overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials
AT seekinsdaniel overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials
AT palmermelissa overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials
AT coffeydenise overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials
AT caminisjohn overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials
AT abdullaevsandzhar overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials
AT patwardhanmeenal overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials
AT tylerhaifa overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials
AT rahejaritu overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials
AT stanleyannmarie overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials
AT pinedasalgadoliliam overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials
AT bourdetdavidl overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials
AT andraderaulj overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials
AT hayashipaulh overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials
AT dimicksantoslara overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials
AT rockeydonc overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials
AT estiloalvin overviewofcausalityassessmentfordruginducedliverinjurydiliinclinicaltrials